Concord Biotech Limited (BOM:543960)

Market Cap	142.55B
Revenue (ttm)	11.25B
Net Income (ttm)	3.24B
Shares Out	n/a
EPS (ttm)	30.89
PE Ratio	44.00
Forward PE	31.86
Dividend	10.70 (0.78%)
Ex-Dividend Date	Sep 3, 2025

Volume	3,107
Average Volume	2,932
Open	1,404.10
Previous Close	1,404.05
Day's Range	1,352.30 - 1,414.40
52-Week Range	1,367.70 - 2,451.65
Beta	n/a
RSI	38.83
Earnings Date	Feb 12, 2026

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin,...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 1,571
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543960

Financial Performance

In 2024, Concord Biotech's revenue was 12.00 billion, an increase of 18.01% compared to the previous year's 10.17 billion. Earnings were 3.72 billion, an increase of 20.62%.